Yakult Seeks Additional Indication For Colon Cancer Drug Elplat
This article was originally published in PharmAsia News
Yakult Honsha applied for an additional indication with Japan's Ministry of Health, Labor and Welfare for Elplat (exaliplatin), a drug approved to treat progressive, recurring colon cancers and colon cancers that cannot be eliminated by surgery. The additional indication is to use the drug as a supplement to chemotherapy after colon cancer surgery. With the July 2009 expiration of patent protection for its major cancer drugCampto (irinotecan), Yakult aims to increase Elplat's target patients and expand the market to increase sales. (Click here for more - Japanese language) "Yakult Applies For Additional Indications For Cancer Drug" - Nikkei Sangyo News (9/2/08)
You may also be interested in...
The MHRA has been working all hours to ensure the standalone medtech UKCA mark works operationally and procedurally in the UK as of 1 January 2021.
Development Partners International, CDC Group and the European Bank for Reconstruction and Development have collaborated to create a “first of its kind, pan-African” generics platform built on the acquisition and combination of Egypt’s Adwia Pharmaceuticals and India’s Celon Laboratories. An initial $250m investment is to be followed by up to $500m in further funding.
Market Brief: Tissue-Engineered Wound Care Market Expected To Reach $1.9BN By 2024 Amid Rising Chronic Disease
The skin replacement market is led by three key players who have all been impacted by COVID-19, but the sector may see a quicker rebound than others as treatments cannot be deferred for a long time.